In October, the FDA approved a 2-dose vaccination regimen for Gardasil 9, for use in girls and boys 9 through 14 years of age. For adolescents, Gardasil 9 can be administered using the 3-dose (0, 2, 6 months) or the 2-dose schedule (0, 6-12 months). For patients 15 through 26 years of age, Gardasil 9 is administered using the 3-dose regimen. For more information about the FDA’s approval, click here.
Additionally, the Advisory Committee on Immunization Practices (ACIP) discussed this schedule modification at their October meeting. The ACIP approved the following recommendation for the human papillomavirus vaccine by majority vote:
– 2-dose schedule for boys and girls initiating HPV vaccination series at 9 to 14 years (0,6-12 months)
– 3-dose schedule for persons initiating HPV vaccination series at older ages
– 3-dose schedule for immunocompromised persons
If the committee’s recommendation is approved by the CDC Director, it will become official once published in MMWR. For more information about the ACIP recommendations, please click here.